Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Sees Large Decrease in Short Interest

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 28,600 shares, a decline of 44.8% from the March 15th total of 51,800 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 73,500 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

Fresenius SE & Co. KGaA Trading Down 0.7 %

Shares of Fresenius SE & Co. KGaA stock traded down $0.08 during trading on Monday, hitting $11.11. The company's stock had a trading volume of 33,745 shares, compared to its average volume of 62,994. The stock has a market cap of $24.82 billion, a price-to-earnings ratio of 52.90 and a beta of 0.86. Fresenius SE & Co. KGaA has a 52 week low of $7.11 and a 52 week high of $11.35. The stock has a 50-day moving average price of $10.50 and a two-hundred day moving average price of $9.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The company had revenue of $6.01 billion for the quarter. Equities research analysts anticipate that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.